FDA Approves First Recombinant Treatment for Rare Blood Clotting Disorder
Adzynma provides a replacement for low levels of the ADAMTS13 enzyme in patients with congenital thrombotic thrombocytopenic purpura.
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - stock.adobe.com
On Nov. 9, 2023, FDA announced the approval of Adzynma, the first genetically engineered protein product for preventative or on-demand enzyme replacement therapy (ERT) for adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). cTTP, a rare and life-threatening blood clotting disorder, is an inherited disorder caused by a mutation in the ADAMTS13 gene, which is responsible for making an enzyme of the same name that regulates blood clotting. cTTP affects an estimated fewer than 1000 people in the United States and can be fatal if left untreated. Treatment has typically involved prophylactic plasma-based therapy for those with chronic disease, to replenish the ADAMTS13 enzyme.
Adzynma is a purified recombinant form of the ADAMTS13 enzyme, and it provides a replacement for low levels of the enzyme in patients with cTTP. For prophylactic (preventative) ERT, Adzynma is given to reduce the risk of disease symptoms. It can also be given as an on-demand ERT for treatment when a patient is experiencing sudden and severe symptoms. Adzynma is administered intravenously once every other week for prophylactic ERT, and once daily for on-demand ERT.
“Without treatment, cTTP is ultimately fatal,” said Peter Marks, director of FDA’s Center for Biologics Evaluation and Research, in a FDA press release. “Today’s approval reflects important progress in the development of much-needed treatment options for patients affected by this life-threatening disorder.”
FDA’s approval was based on a global study evaluating prophylactic and on-demand ERT with Adzynma compared to plasma-based therapies in patients with cTTP. The application for Adzynma was awarded a Rare Pediatric Disease Priority Review Voucher, and was granted Priority Review, Fast Track, and Orphan designations. FDA granted approval of Adzynma to Takeda Pharmaceuticals U.S.A. Inc.
Source: FDA
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
